Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
2348 On Other Exchanges
2348 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

dawnrays pharmaceutical hold (2348) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DAWNRAYS PHARMACEUTICAL HOLD (2348)

Related News

No related news articles were found.

dawnrays pharmaceutical hold (2348) Related Businessweek News

No Related Businessweek News Found

dawnrays pharmaceutical hold (2348) Details

Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. The company operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. It offers cephalosporin antibiotics cover intermediates, bulk medicines, and powder for injections; and specific medicines covering therapeutic areas for anti-HBV, anti-allergic, cardiovascular system, digestive system, urinary system, and endocrine system with dosage forms of tablets, capsules, and granules. The company was founded in 1995 and is headquartered in Wanchai, Hong Kong. Dawnrays Pharmaceutical (Holdings) Limited is a subsidiary of Fortune United Group Limited.

1,008 Employees
Last Reported Date: 09/4/15
Founded in 1995

dawnrays pharmaceutical hold (2348) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: CNY867.0K
Co-Founder and Executive Director
Total Annual Compensation: CNY534.0K
Executive Director
Total Annual Compensation: CNY534.0K
Compensation as of Fiscal Year 2014.

dawnrays pharmaceutical hold (2348) Key Developments

Dawnrays Pharmaceutical Holdings Ltd. Presents at 2015 Credit Suisse China Investment Conference, Nov-03-2015

Dawnrays Pharmaceutical Holdings Ltd. Presents at 2015 Credit Suisse China Investment Conference, Nov-03-2015 . Venue: Grand Hyatt Shanghai, Jin Mao Tower, 88 Century Avenue, Pudong, Shanghai, 200121, China.

Dawnrays Pharmaceutical Holdings Ltd. Reports Unaudited Consolidated Cash Flow Results for the Six Months Ended 30 June 2015

Dawnrays Pharmaceutical Holdings Ltd. reported unaudited consolidated cash flow results for the six months ended 30 June 2015. For the six months, the company reported net cash flows from operating activities was RMB 173,214,000 against RMB 205,401,000 a year ago. Purchases of items of property, plant and equipment and construction in progress was RMB 21,909,000 against RMB 35,339,000 a year ago. Purchases of intangible assets was RMB 130,000 against RMB 5,706,000 a year ago.

Dawnrays Pharmaceutical Holdings Ltd. Declares Interim Dividend for the Six Months of 2015 Payable on or About September 23, 2015

Dawnrays Pharmaceutical Holdings Ltd. declared an interim dividend for the year ending 31 December 2015, at HKD 0.030 per share, amounting to a total sum of approximately HKD 24,130,000. Dividend warrants will be dispatched to shareholders on or about September 23, 2015. The record date for the purpose of determining shareholders' entitlement to the interim dividend is September 11, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
2348:HK $6.36 HKD -0.01

2348 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 2348.
View Industry Companies

Industry Analysis


Industry Average

Valuation 2348 Industry Range
Price/Earnings 15.9x
Price/Sales 4.7x
Price/Book 3.1x
Price/Cash Flow 15.9x
TEV/Sales 3.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact DAWNRAYS PHARMACEUTICAL HOLD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at